key: cord-0965993-hnzrc7ys authors: Guaraldi, Pietro title: Autonomic function test during the COVID-19 pandemic: is it safe and sound? date: 2021-02-02 journal: Clin Auton Res DOI: 10.1007/s10286-021-00776-8 sha: bb5f3c6237c16390000a4bd6987a6b4d7b42599c doc_id: 965993 cord_uid: hnzrc7ys nan The coronavirus disease 2019 (COVID-19) pandemic has dramatically impacted healthcare systems worldwide, which have been compelled to take drastic measures to reorganize their services in a very short period to tackle this unprecedented medical emergency. After a lull in cases during the summer of 2020, positive rates rose dramatically during the last months of the year, and we are currently facing a second wave even worse than the first. Consequently, the COVID-19 pandemic has changed the way most medical procedures are to be performed in the future, even longer than what we expected. A challenge for healthcare providers in the provision of adequate medical care is guaranteeing the safety of patients and personnel during routine diagnostic procedures, such as autonomic function testing. Autonomic function testing is essential for detection, quantification, and localization of autonomic dysfunction of several medical conditions, and are relevant to diagnosis, prognosis, and clinical management of patients to improve their quality of life [1] . Furthermore, some have hypothesized that the autonomic nervous system is involved in the pathophysiology of COVID-19 [4, 5] , and that autonomic dysfunction could be part of the spectrum of long-term sequelae in survivors, known as "longhaul COVID" [8] . If this is true, referral for autonomic testing would be expected to rise soon. In fact, some cases of orthostatic intolerance after COVID-19 have been published [7, 10] , although the causal relationship is yet to be defined. In this context, the American Autonomic Society (AAS) [3] and the autonomic disorders scientific panel of the European Academy of Neurology [2] , in the absence of evidence-based randomized trial data addressing these issues, provided safety guidance for autonomic function testing based on the expert opinion of leaders in the field. Our group also provided some practical advice based on current national and international health authorities' recommendations and our experience about how to perform cardiovascular autonomic function testing during the COVID-19 emergency [6] . In this special issue of Clinical Autonomic Research commemorating its 30th anniversary, Sinn and colleagues share their experience in resuming autonomic function testing at Stanford University [9] . Their safety protocol is similar to the one recommended by the AAS statement. It is also the same as our Bologna group [6] . Some differences include (i) the requirement of polymerase chain reaction (PCR) screening no later than 7 days before the autonomic testing; (ii) the use of both a disposable viral filter and a tube during the Valsalva maneuver; and, (iii) the optional use of disposable gowns. No specific parameters define the time and method to circulate and renew the air in the testing rooms, between one patient and the next. Interestingly, between March 16 and August 2, 2020, they assessed a total of 267 patients, none of which developed COVID-19 immediately after the autonomic testing. This is very good news. The study has limitations acknowledged by the authors. For instance, without repeated PCR tests, they could not completely rule out the possibility of asymptomatic patients. In summary, autonomic function testing is safe and can be resumed as long as it is performed following safety protocols. Screening with PCR and the ongoing vaccination campaign may help us further, but should never drive the healthcare professional to underestimate the potential risk of dealing with asymptomatic carriers. It is imperative to Ethics approval The study does not contain clinical studies or patient data. Ethics committee approval was not necessary for this work. The Authors declare that they have no conflict of interest. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Electrodiagnostic assessment of the autonomic nervous system: a consensus statement endorsed by the American Autonomic Society and the International Federation of Clinical Neurophysiology COVID-19: statement by the Autonomic nervous system disorders Scientific Panel Autonomic function testing in the COVID-19 pandemic: an American Autonomic Society position statement The extended autonomic system, dyshomeostasis, and COVID-19 Is "happy hypoxia" in COVID-19 a disorder of autonomic interoception? A hypothesis Testing cardiovascular autonomic function in the COVID-19 era: lessons from Bologna's Autonomic Unit A case report of postural tachycardia syndrome after COVID-19 Long-Haul COVID Autonomic function test during the COVID-19 pandemic: the Stanford experience Acute hyperhidrosis and postural tachycardia in a COVID-19 patient